Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $4.4 million.

  • Agios Pharmaceuticals' Cash from Financing Activities rose 6818.35% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 492.01%. This contributed to the annual value of $14.4 million for FY2024, which is 16582.0% up from last year.
  • According to the latest figures from Q3 2025, Agios Pharmaceuticals' Cash from Financing Activities is $4.4 million, which was up 6818.35% from $65000.0 recorded in Q2 2025.
  • Agios Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $7.3 million during Q1 2021, with a 5-year trough of -$503.5 million in Q2 2021.
  • For the 5-year period, Agios Pharmaceuticals' Cash from Financing Activities averaged around -$38.8 million, with its median value being $1.2 million (2022).
  • As far as peak fluctuations go, Agios Pharmaceuticals' Cash from Financing Activities plummeted by 737914.73% in 2021, and later soared by 375000.0% in 2023.
  • Agios Pharmaceuticals' Cash from Financing Activities (Quarter) stood at -$18.6 million in 2021, then skyrocketed by 100.12% to $22000.0 in 2022, then skyrocketed by 3750.0% to $847000.0 in 2023, then skyrocketed by 471.66% to $4.8 million in 2024, then dropped by 8.41% to $4.4 million in 2025.
  • Its Cash from Financing Activities was $4.4 million in Q3 2025, compared to $65000.0 in Q2 2025 and $1.6 million in Q1 2025.